Clinical Trial

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
Protocol Amendment History 1 change
notable Trial sites expanded: 53 -> 75 locations 2026-08-14
Trial Details
NCT Number NCT06808984
Lead Sponsor Celgene
Conditions Agitation, Alzheimer Disease
Enrollment 120 participants
Start Date 2025-06-09
Primary Completion 2027-11-26 (estimated)
Study Completion 2028-01-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-13